<DOC>
	<DOCNO>NCT00297102</DOCNO>
	<brief_summary>The aim study investigate effect roflumilast exacerbation rate pulmonary function patient chronic obstructive pulmonary disease ( COPD ) . Roflumilast administer orally daily morning one dose level . The study duration last 56 week . The study provide data safety tolerability roflumilast . For additional information ( US patient ) see www.COPDSTUDY.net dial 866-788-2673 ( toll free ) .</brief_summary>
	<brief_title>Effect Roflumilast Exacerbation Rate Patients With Chronic Obstructive Pulmonary Disease ( COPD ) : The AURA Study ( BY217/M2-124 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Main COPD patient least one exacerbation within last year FEV1/FVC ratio ( postbronchodilator ) ≤ 70 % FEV1 ( postbronchodilator ) ≤ 50 % predict Main COPD exacerbation resolve first baseline visit Diagnosis asthma and/or relevant lung disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Roflumilast</keyword>
	<keyword>COPD</keyword>
	<keyword>Chronic obstructive pulmonary disease</keyword>
</DOC>